Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVA337 in diffuse cutaneous systemic sclerosis
2015-001617-27Phase 2Completed
- Sponsor
- Inventiva
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lanifibranor in systemic sclerosis (SSc) (3 arms), sponsored by Inventiva. Primary endpoint: Mean change in modified Rodnan Skin Score. Started Jun 2015; status: completed.
02
Drugs
lanifibranor
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2015-001617-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001617-27.